Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $12,500.00 in Stock

Galectin Therapeutics Inc. (NASDAQ:GALTGet Rating) Director Richard A. Jr. Zordani bought 5,000 shares of the business’s stock in a transaction on Thursday, July 28th. The shares were acquired at an average price of $2.50 per share, for a total transaction of $12,500.00. Following the completion of the transaction, the director now owns 29,583 shares in the company, valued at approximately $73,957.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Galectin Therapeutics Price Performance

NASDAQ GALT opened at $2.26 on Monday. The business has a 50 day simple moving average of $1.51 and a 200 day simple moving average of $1.67. Galectin Therapeutics Inc. has a 52-week low of $1.19 and a 52-week high of $4.24. The company has a debt-to-equity ratio of 79.37, a quick ratio of 3.51 and a current ratio of 3.51. The stock has a market cap of $134.22 million, a price-to-earnings ratio of -3.90 and a beta of 1.55.

Galectin Therapeutics (NASDAQ:GALTGet Rating) last posted its earnings results on Monday, May 16th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.07). Analysts anticipate that Galectin Therapeutics Inc. will post -0.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on GALT shares. HC Wainwright cut their price target on shares of Galectin Therapeutics from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, May 17th. StockNews.com started coverage on shares of Galectin Therapeutics in a research report on Thursday. They issued a “sell” rating on the stock.

Institutional Trading of Galectin Therapeutics

Large investors have recently bought and sold shares of the business. Atria Wealth Solutions Inc. bought a new stake in Galectin Therapeutics during the 1st quarter worth approximately $460,000. State Street Corp grew its stake in shares of Galectin Therapeutics by 9.4% during the 1st quarter. State Street Corp now owns 173,740 shares of the company’s stock worth $280,000 after acquiring an additional 14,981 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Galectin Therapeutics by 21.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 56,184 shares of the company’s stock worth $90,000 after acquiring an additional 10,000 shares in the last quarter. Centaurus Financial Inc. bought a new position in shares of Galectin Therapeutics during the 1st quarter worth approximately $34,000. Finally, Commonwealth Equity Services LLC grew its stake in shares of Galectin Therapeutics by 42.1% during the 2nd quarter. Commonwealth Equity Services LLC now owns 38,220 shares of the company’s stock worth $50,000 after acquiring an additional 11,318 shares in the last quarter. 12.35% of the stock is owned by institutional investors.

About Galectin Therapeutics

(Get Rating)

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.

See Also

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.